Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1437-7772

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment ; volume:25 ; number:5 ; day:3 ; month:4 ; year:2020 ; pages:801-809 ; date:5.2020
International journal of clinical oncology ; 25, Heft 5 (3.4.2020), 801-809, 5.2020

Creator: Sato, Hiro
Okonogi, Noriyuki
Nakano, Takashi

Contributor: SpringerLink (Online service)

DOI: 10.1007/s10147-020-01666-1

URN: urn:nbn:de:101:1-2020071101241368312474

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:54 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Sato, Hiro
Okonogi, Noriyuki
Nakano, Takashi
SpringerLink (Online service)

Other Objects (12)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Related objects

Reset password